Live Virtual Symposium

Introducing HST5040 Being Developed for Methylmalonic and Propionic Acidemias

Tuesday, April 13

1 pm – 2 pm Eastern (6 pm - 7 pm GMT)

CLICK HERE TO REGISTER

PROGRAM

1:00 - 1:05 | Welcome and Introductions

1:05 - 1:15 | Need for improving outcomes in MMA and PA and new approaches entering clinical trials

1:15 - 1:30 | Pharmacology and preclinical data on oral small molecule HST5040

1:30 - 1:45 | HERO phase 2 clinical study design

1:45 - 2:00 | Moderated Questions and Answers

MODERATOR

Gregory Enns, MD
Professor of Pediatrics, Stanford University

PRESENTERS

Kimberly Chapman, MD, PhD
Geneticist and Metabolist, Children’s National Hospital

Brian Wamhoff, PhD
Co-Founder and Chief Operating Officer, HemoShear Therapeutics

Gerald Cox, MD, PhD
Chief Medical Officer, HemoShear Therapeutics

REGISTER NOW

PUBLICATION

Molecular Genetics and Metabolism has published in vitro pharmacology data supporting the oral small molecule HST5040 as a potential novel treatment for MMA and PA.